Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan

BACKGROUND: Sarilumab is a human immunoglobulin G1 anti-interleukin-6 (IL-6) receptor monoclonal antibody that blocks IL-6 from binding to membrane-bound and soluble IL-6 receptor α. This bridging study assessed the efficacy and safety of sarilumab + methotrexate (MTX) in Japanese patients with acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yoshiya, Wada, Kazuteru, Takahashi, Yoshinori, Hagino, Owen, van Hoogstraten, Hubert, Graham, Neil M. H., Kameda, Hideto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425658/
https://www.ncbi.nlm.nih.gov/pubmed/30894208
http://dx.doi.org/10.1186/s13075-019-1856-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425658/
https://www.ncbi.nlm.nih.gov/pubmed/30894208
http://dx.doi.org/10.1186/s13075-019-1856-4

Ejemplares similares